These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 7038095)

  • 1. Assessment of the extent to exogenous prostaglandin I2 is converted to 6-keto-prostaglandin E1 in human subjects.
    Jackson EK; Goodman RP; Fitzgerald GA; Oates JA; Branch RA
    J Pharmacol Exp Ther; 1982 Apr; 221(1):183-7. PubMed ID: 7038095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 6-Keto-prostaglandin E1 is more potent than prostaglandin I2 as a renal vasodilator and renin secretagogue.
    Jackson EK; Herzer WA; Zimmerman JB; Branch RA; Oates JA; Gerkens JF
    J Pharmacol Exp Ther; 1981 Jan; 216(1):24-7. PubMed ID: 7005428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 6-Keto-prostaglandin E1 is a potent coronary vasodilator and stimulates a vagal reflex in dogs.
    Panzenbeck MJ; Hintze TH; Kaley G
    J Pharmacol Exp Ther; 1988 Mar; 244(3):814-9. PubMed ID: 3075239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of the effects of prostacyclin and 6-keto-prostaglandin E1 on renin release in the isolated rat and rabbit kidney.
    Schwertschlag U; Stahl T; Hackenthal E
    Prostaglandins; 1982 Jan; 23(1):129-38. PubMed ID: 7038776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-blind study of epoprostenol and 6-keto-prostaglandin E1 in man: effects of platelet aggregation and plasma renin.
    Miyamori I; Morise T; Yasuhara S; Takeda Y; Koshida H; Takeda R
    Br J Clin Pharmacol; 1985 Dec; 20(6):681-3. PubMed ID: 3912001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elimination from the circulation of cats of 6-keto-prostaglandin E1 compared with prostaglandins E2 and I2.
    Förstermann U; Neufang B
    J Pharm Pharmacol; 1983 Nov; 35(11):724-8. PubMed ID: 6139453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the pulmonary, hepatic and renal extraction of PGI2 and 6-keto-PGE1.
    Tsunoda S; Jackson EK; Branch RA; Gerkens JF
    Eur J Pharmacol; 1982 Jan; 77(2-3):147-51. PubMed ID: 7037431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolism of prostacyclin: formation of an active metabolite in the liver.
    Wong PY; Lee WH; Quilley CP; McGiff JC
    Fed Proc; 1981 May; 40(7):2001-4. PubMed ID: 7014260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of intravitreal and topical prostaglandins on intraocular inflammation.
    Kulkarni PS; Srinivasan BD
    Invest Ophthalmol Vis Sci; 1982 Sep; 23(3):383-92. PubMed ID: 7050005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A radioimmunoassay for the unstable pulmonary metabolites of prostaglandin E1 and E2: an indirect index of their in vivo disposition and pharmacokinetics.
    Bothwell W; Verburg M; Wynalda M; Daniels EG; Fitzpatrick FA
    J Pharmacol Exp Ther; 1982 Feb; 220(2):229-35. PubMed ID: 6948952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolism of prostacyclin and 6-keto-prostaglandin F1 alpha in man.
    Rosenkranz B; Fischer C; Reimann I; Weimer KE; Beck G; Frölich JC
    Artery; 1980; 8(1):18-22. PubMed ID: 7000039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of 6-keto-prostaglandin E1 obtained from isolated perfused kidney of the rabbit.
    Pieroni JP; Dray F; Pace-Asciak CR; McGiff JC
    J Pharmacol Exp Ther; 1988 Oct; 247(1):63-8. PubMed ID: 3139870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasodilator actions of prostaglandin 6-keto-E1 in the pulmonary vascular bed.
    Hyman AL; Kadowitz PJ
    J Pharmacol Exp Ther; 1980 Jun; 213(3):468-72. PubMed ID: 7193724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 6-keto-prostaglandin E1 is not equipotent to prostacyclin (PGI2) as an antiaggregatory agent.
    Miller OV; Aiken JW; Shebuski RJ; Gorman RR
    Prostaglandins; 1980 Aug; 20(2):391-400. PubMed ID: 6251513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic disposition of prostacyclin in humans.
    Brash AR; Jackson EK; Saggese CA; Lawson JA; Oates JA; FitzGerald GA
    J Pharmacol Exp Ther; 1983 Jul; 226(1):78-87. PubMed ID: 6345756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Placental vascular responses to 6-keto-prostaglandin E1 in the near-term sheep.
    Schwartz DB; Phernetton TM; Stock MK; Rankin JH
    Am J Obstet Gynecol; 1983 Feb; 145(4):406-10. PubMed ID: 6337494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Metabolism of intravenously administered prostaglandin E1 in patients with peripheral arterial occlusive disease].
    Hesse WH; Rudofsky G; Peskar BA
    Wien Klin Wochenschr; 1991; 103(18):554-7. PubMed ID: 1750222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the prostacyclin products, 6-keto prostaglandin E1 and 6-keto prostaglandin F1 alpha, on bone resorption in vitro.
    Neuman SD; Raisz LG
    Prostaglandins Leukot Med; 1984 Jul; 15(1):103-8. PubMed ID: 6382342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythropoietic effects of prostacyclin (PGI2) and its metabolite 6-keto-prostaglandin (PG)E1.
    Nelson PK; Brookins J; Fisher JW
    J Pharmacol Exp Ther; 1983 Aug; 226(2):493-9. PubMed ID: 6410047
    [No Abstract]   [Full Text] [Related]  

  • 20. Conversion of prostacyclin to 6 oxo prostaglandin E1 by rat, rabbit, guinea-pig and human platelets.
    Griffiths RJ; Moore PK
    Br J Pharmacol; 1983 Oct; 80(2):395-402. PubMed ID: 6360281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.